Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743575 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL1290220 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL14632099 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL124776 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL612826 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL13719286 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL1305814 | 0.89 | GABRA5 (0.40) | SLC6A4SLC6A2SLC6A3SLC6A1GABRA5 | |
| SCHEMBL1564564 | 0.88 | SLC6A1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL16763685 | 0.88 | SLC6A1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL16763687 | 0.88 | SLC6A1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | disclosed |
| CN-118119620-A | Pharmaceutical composition for treating tumors and application thereof | 南京再明医药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023083283-A1 | DRUG COMBINATION FOR TREATING TUMOR, AND APPLICATION THEREOF | 先声药业有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-115836068-A | Pyrrolidine compounds and application thereof | 先声药业有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| CN-115557946-A | Heterocyclic lactam compound, pharmaceutical composition containing same and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022247919-A1 | COMPOUND USED AS BCR-ABL INHIBITOR | 正大天晴药业集团股份有限公司 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-2411010-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-8044068-B2 | Aminopyrrolidine compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011034215-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-24 | — | — | WO | disclosed |
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7795256-B2 | Thieno-pyridinone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2007-04-05 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | SLC6A4 3799/4885SLC6A2 3487/4885SLC6A3 3644/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | SLC6A4 1759/4885SLC6A2 2462/4885SLC6A3 1868/4885 |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SLC6A4 249/4885SLC6A2 492/4885SLC6A3 522/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | SLC6A4 198/4885SLC6A2 179/4885SLC6A3 193/4885 |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | MAP3K6, MAP4K2, MAP3K15 | SLC6A4 3390/4885SLC6A2 3381/4885SLC6A3 3717/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | SLC6A4 406/4885SLC6A2 300/4885SLC6A3 736/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | SLC6A4 56/4885SLC6A2 135/4885SLC6A3 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.